TargetBeta
WRN
WRN RecQ like helicase · also RECQL2, RECQ3 · Exonucleases
6 programs in company-led studies act on WRN, from 6 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| WRN Inhibitor RO7589831rule | Bayer | phase 2 | 22 running | – | NCIt |
| WRN Inhibitor EIK1005rule | Eikon Therapeutics | phase 2 | 11 running | – | NCIt |
| WRN Inhibitor GSK4418959rule | GlaxoSmithKline | phase 2 | 11 running | – | NCIt |
| WRN Inhibitor NDI-219216rule | Nimbus Wadjet | phase 2 | 11 running | – | NCIt |
| WRN Inhibitor AMG 436rule | Amgen | phase 1 | 11 running | – | NCIt |
| WRN Inhibitor MOMA-341rule | MOMA Therapeutics | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Colorectal Neoplasms, 2 programs
- Neoplasm Metastasis, 2 programs
- Colorectal Neoplasms, Hereditary Nonpolyposis, 1 program
- Endometrial Neoplasms, 1 program
- Microsatellite Instability, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 31, 2027WRN Inhibitor RO7589831 · Bayer · phase 2 · NCT06004245
- Nov 2027WRN Inhibitor MOMA-341 · MOMA Therapeutics · phase 1 · NCT06974110
- Mar 2029WRN Inhibitor EIK1005 · Eikon Therapeutics · phase 2 · NCT07262619
- Jan 1, 2030WRN Inhibitor AMG 436 · Amgen · phase 1 · NCT07403721
- Oct 2031WRN Inhibitor NDI-219216 · Nimbus Wadjet · phase 2 · NCT06898450
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.